<?xml version="1.0" encoding="UTF-8"?>
<p>The 12‐week trial consisted of 4 groups of 10 mice with congenital myasthenia, receiving no treatment, pyridostigmine, salbutamol, or pyridostigmine to which salbutamol was added mid‐trial.</p>
